In this Article

• What is aspirin?
• What are antiplatelet agents and how do they work?
• What is dipyridamole?
• When is aspirin used for preventing and treating heart attacks and strokes?
• Treatment of heart attacks
• Treatment of exertional and unstable angina
• Treatment of ischemic strokes
• How effective is aspirin for preventing heart attacks among healthy subjects?
• What are the side effects of aspirin?
• What is aspirin allergy?
• What is the optimal dose of aspirin for treating and preventing heart attacks and strokes?
• Who should be taking aspirin to prevent heart attacks and strokes?
• Who should not be taking aspirin?
• What interactions might aspirin have with other medications?
• What can be done to reduce the risk of ulcers from long-term aspirin use?
• What are the limitations of aspirin treatment?
• What is aspirin resistance?
• What is in the future for the research on aspirin resistance?
• Aspirin and Antiplatelet Medications Glossary
• Aspirin and Antiplatelet Medications Index

What is aspirin resistance?

Aspirin resistance can be defined as the lack of antiplatelet effect despite therapeutic doses of aspirin (75mg-150mg/day for at least five days). This lack of anti-platelet response to aspirin increases the risk of developing heart attacks, strokes, and related deaths. Aspirin resistance is different from other causes of aspirin failure (see above), such as patient non-compliance or drug interference from concomitant use of ibuprofen.

Some scientists believe that a segment of the population is resistant to the antiplatelet effect of aspirin. In these aspirin-resistant individuals, aspirin does not inhibit the formation of thromboxane A-2. Resistant individuals can be identified in research settings by finding high levels of 11-dehydrothromboxane B2 (a metabolic breakdown product of thromboxane A-2) in the urine while taking aspirin. These individuals have a higher risk of heart attack and strokes than subjects with lower urine levels of 11-dehydrothromboxane B2.

Another way of identifying aspirin resistance in research settings is by optical platelet aggregation. Aspirin nonresponders identified by this method were found to have higher rates of heart attacks, strokes, and death than aspirin responders.

What is in the future for the research on aspirin resistance?

While research scientists are increasingly convinced that aspirin resistance exists, there are no reliable and standardized tests that doctors in clinical practice can use to diagnose this condition. Large scale controlled studies are needed to validate and standardize laboratory tests of aspirin resistance, and link these tests results to clinical outcomes.

Clinical trials will also be needed to determine how best to treat aspirin resistance. For example, should patients diagnosed as having aspirin resistance be treated with higher doses of aspirin? Should they be treated with aspirin in combination with another anti-platelet agent? Or should they be treated with a different anti-platelet agent, such as clopidogrel bisulfate (Plavix)?

References:
U.S. Preventive Services Task Force; "Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement;" Annals of Internal Medicine; 17 March 2009. Volume 150 Issue 6. Pages 396-404.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988), "Randomized Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2", The Lancet 332: 349-360
Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, et al.; "Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial." N Engl J Med. 1985 Nov 28;313(22):1369-75.
Theroux P; Ouimet H; McCans J; Latour JG; Joly P; Levy G; Pelletier E; Juneau M; Stasiak J; deGuise P; et al. "Aspirin, heparin, or both to treat acute unstable angina." Journal of Medicine Vol. 319:1105-1111
LC Wallentin; "Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden"J Am Coll Cardiol, 1991; 18:1587-1593
C. H. Hennekens, MD; M. L. Dyken, MD; V. Fuster, MD. "Aspirin as a Therapeutic Agent in Cardiovascular Disease;" Circulation. 1997;96:2751-2753

Previous contributing author: Dennis Lee, M.D.

Suggested Reading by Our Doctors

• Nonsteroidal Antiinflammatory Drugs (NSAIDs) - Describes Nonsteroidal Antiinflammatory Drugs (NSAIDs), which are medications used primarily to treat inflammation, mild to moderate pain, and fever.
• Coronary Artery Bypass Graft - Read about heart bypass surgery (coronary artery bypass graft surgery, CABG) including how coronary artery disease is diagnosed, treated, recovery time, risks and complications, and the long term results after CABG.
• Lupus - Get information on lupus (SLE) disease treatment, signs, diagnosis, types of symptoms (butterfly, discoid rash), causes, pregnancy flares, prevention and statistics.

Read more Aspirin and Antiplatelet Medications related articles »

Latest Medical News

• Experts Revise Guidelines on Daily Aspirin for Heart
• Plavix, PPI Combo: Risky for Heart Patients?
• Older Americans Take Risky Drug Combos